Neo-Angin dolo

Informazioni principali

  • Nome commerciale:
  • Neo-Angin dolo Lutschtabletten
  • Forma farmaceutica:
  • Lutschtabletten
  • Composizione:
  • flurbiprofenum 8.75 mg, aromatica, excipiens pro pastillo.
  • Utilizzare per:
  • Esseri umani
  • Tipo di medicina:
  • Farmaco biologico

Documenti

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • Neo-Angin dolo Lutschtabletten
    Svizzera
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • Synthetika
  • Area terapeutica:
  • kurzzeitige symptomatische Behandlung bei schmerzhaften Entzündungen der Rachenschleimhaut

Altre informazioni

Status

  • Fonte:
  • Swissmedic - Swiss Agency for Therapeutic Products
  • Numero dell'autorizzazione:
  • 66706
  • Data dell'autorizzazione:
  • 07-06-2018
  • Ultimo aggiornamento:
  • 19-10-2018

Foglio illustrativo

Patienteninformation

neo-angin dolo, pastiglie

Doetsch Grether AG

Che cos'è neo-angin dolo e quando si usa?

neo-angin dolo, pastiglie, contiene il principio attivo flurbiprofene. neo-angin dolo è un farmaco

indicato per il trattamento di breve durata, ossia per 3 giorni al massimo, delle infiammazioni della

mucosa della gola accompagnate da dolore.

L'instaurazione dell'effetto si è osservata circa 30 - 40 minuti dopo l'uso.

Di che cosa occorre inoltre tener conto durante il trattamento?

Avvertenza per i diabetici:

neo-angin dolo pastiglie: questo medicamento contiene 2,5 g di carboidrati digeribili per ogni

pastiglia.

Le pastiglie di neo-angin dolo contengono zucchero, quindi possono favorire l'insorgenza di carie.

Perciò è necessaria un'accurata igiene orale.

Quando non si può usare neo-angin dolo?

·Se ha un'ipersensibilità al principio attivo flurbiprofene o ad altri antinfiammatori (antireumatici),

analgesici e antipiretici (es. acido acetilsalicilico, aspirina). Un'ipersensibilità a questi farmaci si

manifesta per esempio con asma, mancanza di respiro, disturbi circolatori, gonfiore della pelle e delle

mucose o eruzioni cutanee (orticaria).

·Durante la gravidanza o l'allattamento (vedi anche «Si può somministrare neo-angin dolo durante la

gravidanza o l'allattamento?»)

·Se soffre di un'ulcera gastrica o duodenale o di emorragie gastrointestinali;

·Nei bambini di età inferiore ai 12 anni. neo-angin dolo non è ancora stato testato nei bambini minori

di 12 anni.

·Se soffre di disturbi emorragici, emopoietici (di produzione delle cellule del sangue) o della

coagulazione.

·Se soffre d'intolleranza ad alcuni tipi di zuccheri.

·In caso d'insufficienza cardiaca o di grave insufficienza renale o epatica.

Quando è richiesta prudenza nella somministrazione di neo-angin dolo?

Nelle seguenti situazioni l'uso di neo-angin dolo è concesso solo su prescrizione medica e sotto

controllo medico:

·se soffre d'asma;

·se nel passato ha sofferto di ulcera gastrica o duodenale;

·se soffre di un disturbo dei reni o del fegato;

·se è in cura per una malattia del cuore, in particolare un'insufficienza cardiaca o un'ipertensione

arteriosa;

·se riceve un trattamento con anticoagulanti (farmaci che mantengono liquido il sangue) o se soffre

di un disturbo della coagulazione;

·se assume farmaci antireumatici o altri analgesici (es. acido acetilsalicilico, aspirina);

·se soffre di una malattia autoimmune cronica come il lupus eritematoso sistemico (LES) o la

connettivite mista;

·se è anziano, perché potrebbe avere una maggiore probabilità di sviluppare gli effetti collaterali

elencati in questo foglietto illustrativo.

Interrompa l'assunzione delle pastiglie al primo segno di reazioni cutanee (eruzione cutanea,

desquamazione della pelle, formazione di vesciche) o in presenza di altri segni di una reazione

allergica e si rivolga immediatamente a un medico. Informi il suo medico se manifesta sintomi

gastrici insoliti (soprattutto emorragie).

Se nota un peggioramento dei sintomi o la comparsa di nuovi disturbi (es. febbre, difficoltà di

deglutizione), deve consultare un medico.

Informi il suo medico o il suo farmacista se soffre di altre malattie, soffre di allergie o usa altri

medicamenti (anche se acquistati di propria iniziativa!).

Si può impiegare neo-angin dolo durante la gravidanza o l'allattamento?

neo-angin dolo non può essere utilizzato durante la gravidanza o l'allattamento, a meno che non

l'abbia esplicitamente prescritto il medico. Importante: nell'ultimo trimestre di gravidanza e durante

l'allattamento, l'uso di neo-angin dolo è in linea di principio vietato.

neo-angin dolo fa parte di un gruppo di medicamenti che possono compromettere la fertilità delle

donne. Questo effetto è reversibile dopo l'interruzione dell'assunzione delle pastiglie. È improbabile

che l'uso occasionale di neo-angin dolo influenzi la possibilità di restare incinte. Tuttavia, se ha

difficoltà a restare incinta, parli con il suo medico prima di utilizzare questo medicamento.

Come usare neo-angin dolo?

Adulti e adolescenti dai 12 anni:

Lasciar sciogliere lentamente in bocca una pastiglia ogni 3-6 ore. La dose totale giornaliera non deve

superare 5 pastiglie.

Come con tutte le pastiglie, per evitare che la mucosa orale si irriti si consiglia di muovere

continuamente la pastiglia mentre la si succhia. Se insorgono irritazioni nella bocca, interrompere il

trattamento con neo-angin dolo.

Non utilizzi neo-angin dolo per più di 3 giorni e lo usi solo per trattare i disturbi indicati all'inizio.

Impieghi il numero minimo di pastiglie richieste per l'attenuazione dei sintomi, e solo per il tempo

necessario. Se i disturbi non migliorano al più tardi entro 3 giorni, consulti il medico per chiarirne la

causa.

Bambini di età inferiore ai 12 anni:

neo-angin dolo non può essere somministrato a bambini minori di 12 anni.

Pazienti anziani:

Gli anziani possono reagire al medicamento in modo più sensibile rispetto ai giovani adulti. È quindi

particolarmente importante che i pazienti anziani notifichino subito eventuali effetti collaterali al

medico o al farmacista.

Si attenga alla posologia indicata nel foglietto illustrativo o prescritta dal medico. Se ritiene che

l'azione del medicamento sia troppo debole o troppo forte ne parli al suo medico o al suo farmacista.

Quali effetti collaterali può avere neo-angin dolo?

Con l'assunzione di neo-angin dolo possono manifestarsi i seguenti effetti collaterali, che in

particolari circostanze potrebbero richiedere un trattamento medico.

Molto frequenti: sensazione di fastidio in bocca (calore, bruciore o prurito).

Frequenti: diarrea, nausea, ulcere nella mucosa orale, secchezza della bocca, dolore alla bocca,

irritazione della faringe, vertigini, mal di testa.

Occasionali: sonnolenza, formazione di vesciche nell'orofaringe, ridotta sensibilità della gola,

flatulenza, vomito, disturbi digestivi, bruciore di stomaco o dolori nella parte superiore dell'addome,

gonfiore di stomaco, costipazione, alterazione del senso del gusto, disturbi cutanei come eruzioni

cutanee e prurito, peggioramento dell'asma, respiro sibilante, fiato corto, stanchezza o difficoltà ad

addormentarsi, febbre, dolori.

Rari: reazioni anafilattiche.

Casi isolati: anemia, basso numero di piastrine, gonfiore, ipertensione, insufficienza cardiaca, gravi

reazioni cutanee (come formazione di vesciche), epatite.

Se osserva effetti collaterali qui non descritti dovrebbe informare il suo medico o il suo farmacista.

Di che altro occorre tener conto?

Stabilità:

Il medicamento non dev'essere utilizzato oltre la data indicata con «EXP» sulla confezione.

Conservazione/stoccaggio:

Conservare neo-angin dolo nella sua confezione originale e a temperatura non superiore ai 30 °C.

Tenere fuori dalla portata dei bambini.

Il medico o il farmacista, che sono in possesso di documentazione professionale, possono darle

ulteriori informazioni.

Che cosa contiene neo-angin dolo?

Una pastiglia di neo-angin dolo contiene:

Principio attivo: flurbiprofene 8,75 mg

Sostanze ausiliarie: magrogol 300, aromi (olio di menta piperita, levomentolo), sciroppo di glucosio,

saccarosio

Numero dell’omologazione

66706 (Swissmedic)

Dov'è ottenibile neo-angin dolo? Quali confezioni sono disponibili?

In farmacia senza prescrizione medica.

neo-angin dolo è disponibile in confezioni da 16 pastiglie.

Titolare dell'omologazione

Doetsch Grether AG, 4051 Basel.

Questo foglietto illustrativo è stato controllato l'ultima volta nel marzo 2017 dall'autorità competente

in materia di medicamenti (Swissmedic).

15-11-2018

Recommendations on the use of the proportionality approach in the framework of risk assessment for pesticide residues

Recommendations on the use of the proportionality approach in the framework of risk assessment for pesticide residues

Published on: Wed, 14 Nov 2018 The technical report reflects the outcome of the discussions and agreements that were reached in the pesticides peer review meeting on residues and maximum residue levels regarding the principles and guidance for application of the proportionality concept in the risk assessment methodologies used at European level for the estimation of the maximum residue levels for pesticides. In addition, practical experiences on the use of the proportionality approach gained by EFSA hav...

Europe - EFSA - European Food Safety Authority Publications

26-10-2018

Safety and efficacy of l‐threonine produced by fermentation using Escherichia coli CGMCC 7.232 for all animal species

Safety and efficacy of l‐threonine produced by fermentation using Escherichia coli CGMCC 7.232 for all animal species

Published on: Thu, 25 Oct 2018 00:00:00 +0200 The product subject of this assessment is l‐threonine produced by fermentation with a genetically modified strain of Escherichia coli (CGMCC 7.232). It is intended to be used in feed and water for drinking for all animal species and categories. The production strain and its recombinant DNA were not detected in the additive. The product l‐threonine, manufactured by fermentation with E. coli CGMCC 7.232, does not raise any safety concern with regard to the gen...

Europe - EFSA - European Food Safety Authority Publications

11-10-2018

Wild boar in focus: Review of existing models on spatial distribution and density of wild boar and proposal for next steps

Wild boar in focus: Review of existing models on spatial distribution and density of wild boar and proposal for next steps

Published on: Wed, 10 Oct 2018 00:00:00 +0200 This report provides a review of existing models for predicting the spatial distribution and abundance of wild boar at various scales (global, continental, national and regional) in order to inform the development of a new model to produce estimates of wild boar abundance at European level. The review identifies and discusses a range of models based on a wide variety of data types, corresponding to those targeted by the data collection model set by ENETwild,...

Europe - EFSA - European Food Safety Authority Publications

19-9-2018

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

Published on: Tue, 18 Sep 2018 00:00:00 +0200 During the years 2012‐2016, the Dutch National Food Consumption survey was conducted in the Netherlands. For the survey, a random sample was drawn from consumer panels stratified by age and gender and maintained representative to the population with regard to region, address density and educational level. Complete results were obtained for 4,313 persons (response rate 65%); including toddlers, children, adolescents, adults and elderly. Pregnant or lactating ...

Europe - EFSA - European Food Safety Authority Publications

14-9-2018

Development of an automated multienzymatic biosensor for risk assessment of pesticide contamination in water and food

Development of an automated multienzymatic biosensor for risk assessment of pesticide contamination in water and food

Published on: Mon, 27 Aug 2018 00:00:00 +0200 The goal of this research is to better address the problems related to the widespread presence of pesticides in the environment. Despite the unquestionable utility of the pesticides against various pests in the agricultural field, most pesticides and the corresponding pesticide residues are toxic to the environment and hazardous to human health. The recent literature on organophosphate compounds emphasises a clear correlation between their use and the occurr...

Europe - EFSA - European Food Safety Authority Publications

13-9-2018

BioLyte Laboratories Issues Voluntary Nationwide Recall Due to the Voluntary Nationwide Recall initiated by King Bio Inc. (a Raw Material Supplier) for NeoRelief for Muscle Cramping and Restlessness Topical Gel Due to Possible Microbial Contamination

BioLyte Laboratories Issues Voluntary Nationwide Recall Due to the Voluntary Nationwide Recall initiated by King Bio Inc. (a Raw Material Supplier) for NeoRelief for Muscle Cramping and Restlessness Topical Gel Due to Possible Microbial Contamination

BioLyte Laboratories is voluntarily recalling lot numbers 1138, 1139, 1146, and 1160 of NeoRelief for Muscle Cramping and Restlessness Topical Gel to the retail and consumer level. King Bio Inc., a manufacturer of some of the active ingredients in this product, has been found to have some water contamination issues that potentially could have affected this product. King Bio has issued a recall of these active ingredients in BioLyte’s lot specific product. To date, there have been no reports of illness or...

FDA - U.S. Food and Drug Administration

13-9-2018

Use of next‐generation sequencing in microbial risk assessment

Use of next‐generation sequencing in microbial risk assessment

Published on: Mon, 27 Aug 2018 00:00:00 +0200 Despite the ever increase in rigorous control and monitoring measures to assure safe food along the entire farm‐to‐fork chain, the past decade has also witnessed an increase in microbial food alerts. Hence, research on food safety and quality remain of utmost importance. Complementary, and at least as important, is the necessity to be able to assess the potential microbial risks along the food chain. Risk assessment relies on sound scientific data. Unfortuna...

Europe - EFSA - European Food Safety Authority Publications

12-9-2018

Application of data science in risk assessment and early warning

Application of data science in risk assessment and early warning

Published on: Mon, 27 Aug 2018 00:00:00 +0200 The currently applied approaches, procedures and tools used for the identification of emerging risks vary greatly among Member States of the EU. EFSA established a structured approach for emerging risk identification that mainly consists of systematically searching, collecting, collating and analysing information and data. In addition, EFSA concluded that new methodologies and tools are needed to facilitate efficient and transparent sharing of data, knowledg...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Risk assessment of substances used in food supplements: the example of the botanical Gymnema sylvestre

Risk assessment of substances used in food supplements: the example of the botanical Gymnema sylvestre

Published on: Tue, 28 Aug 2018 00:00:00 +0200 Botanicals and preparations derived from these are among the substances frequently added to foods and food supplements, yet the safety of many botanicals has not been systematically assessed. In the context of the EU‐FORA fellowship programme, the fellow performed an assessment on the safety of the botanical Gymnema sylvestre, in accordance with EFSA's guidance on the assessment of safety of botanicals. Although preparations of G. sylvestre are marketed as f...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Novel foods: a risk profile for the house cricket (Acheta domesticus)

Novel foods: a risk profile for the house cricket (Acheta domesticus)

Published on: Tue, 28 Aug 2018 00:00:00 +0200 Novel foods could represent a sustainable alternative to traditional farming and conventional foodstuffs. Starting in 2018, Regulation (EU) 2283/2015 entered into force, laying down provisions for the approval of novel foods in Europe, including insects. This Approved Regulation establishes the requirements that enable Food Business Operators to bring new foods into the EU market, while ensuring high levels of food safety for European consumers. The present ...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Risk assessment of antimicrobial resistance along the food chain through culture‐independent methodologies

Risk assessment of antimicrobial resistance along the food chain through culture‐independent methodologies

Published on: Mon, 27 Aug 2018 00:00:00 +0200 Antimicrobial resistance (AMR) represents a major challenge for Public Health and the scientific community, and requires immediate and drastic solutions. Acquired resistance to certain antimicrobials is already widespread to such an extent that their efficacy in the treatment of certain life‐threatening infections is already compromised. To date, the emergence and spread of AMR has been attributed to the use, misuse or indiscriminate use of antibiotics as th...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Assessment of occupational and dietary exposure to pesticide residues

Assessment of occupational and dietary exposure to pesticide residues

Published on: Mon, 27 Aug 2018 00:00:00 +0200 Plant protection products (PPPs) are pesticides containing at least one active substance that drives specific actions against pests (diseases). PPPs are regulated in the EU and cannot be placed on the market or used without prior authorisation. EFSA assesses the possible risks of the use of active substances to humans and environment. Member States decide whether or not to approve their use at EU level. Furthermore, Member States decide at national level on ...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Explanatory note on the determination of newly expressed protein levels in the context of genetically modified plant applications for EU market authorisation

Explanatory note on the determination of newly expressed protein levels in the context of genetically modified plant applications for EU market authorisation

Published on: Mon, 20 Aug 2018 00:00:00 +0200 Genetically modified organisms are subject to a risk assessment and regulatory approval before entering the European market. According to legislation (Directive 2001/18/EC, Regulation (EC) No 1829/2003 and Regulation (EU) No 503/2013) and the EFSA guidance documents on the risk assessment of food and feed from genetically modified (GM) plants and on the environmental risk assessment of GM plants, applicants need to perform a molecular characterisation of any...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Strategic partnership with German data providing institutions on data quality (Pilot project) – Final report

Strategic partnership with German data providing institutions on data quality (Pilot project) – Final report

Published on: Tue, 07 Aug 2018 00:00:00 +0200 This report describes the framework of collection, management and transmission of food safety data in the Federal Republic of Germany. To adjust optimally the data governance processes to the requirements defined by the EFSA, measures had been agreed upon in order to improve the specified situation. Subsequent methodological system enhancements related to data quality are given as well as structural adjustments and the development and implementation of suppo...

Europe - EFSA - European Food Safety Authority Publications

14-8-2018

The Uttermost Company recalls Various Types of Mirrors, Art and Wall Décor sold with Adjustable J-Hook Hanging Hardware

The Uttermost Company recalls Various Types of Mirrors, Art and Wall Décor sold with Adjustable J-Hook Hanging Hardware

The hanging hardware can break, causing mirrors and wall décor to fall from walls, posing an injury hazard to bystanders.

Health Canada

14-8-2018

Neo-Image Candlelight Ltd recalls Thermoglow Stem Wick Chafing fuel & Thermoglow Methanol Gel Chafing Fuel

Neo-Image Candlelight Ltd recalls Thermoglow Stem Wick Chafing fuel & Thermoglow Methanol Gel Chafing Fuel

The recalled products do not have proper hazard labelling as required by the Consumer Chemicals and Containers Regulations, 2001 under the Canada Consumer Product Safety Act. Improper labelling could result in unintentional exposure to these products and lead to serious illness, injury or death.

Health Canada

11-7-2018

Yakima Products Inc. recalls Yakima HoldUp EVO Bicycle Carriers

Yakima Products Inc. recalls Yakima HoldUp EVO Bicycle Carriers

The snap pins can become loose and fall out causing the rear wheel cup (and rear wheel) to detach from the main frame. Prior warnings of this defect may include sliding or banging noises when the rear wheel and wheel cup hits the ground. This can result in a bicycle ejection, causing a crash or personal injury to persons outside the vehicle.

Health Canada

2-7-2018

Fagron Sterile Services Issues Voluntary Nationwide Recall of Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL and Neostigmine Methylsulfate 1mg/mL, 3mg per 3mL, in a 5mL syringe Due to Mislabeling

Fagron Sterile Services Issues Voluntary Nationwide Recall of Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL and Neostigmine Methylsulfate 1mg/mL, 3mg per 3mL, in a 5mL syringe Due to Mislabeling

Fagron Sterile Services is voluntarily recalling two (2) lots of Neostigmine Methylsulfate 5mL syringes to the user/hospital/clinic level. The specified product lots are being recalled because of a confirmed customer complaint that some syringe units containing Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL are incorrectly labelled as Neostigmine Methylsulfate 1mg/mL, 3mg per 3mL. Secondary packages are properly labelled as Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL.

FDA - U.S. Food and Drug Administration

19-6-2018

Various Aortic Endovascular Graft Systems: Letter to Health Care Providers - UPDATE on Type III Endoleaks

Various Aortic Endovascular Graft Systems: Letter to Health Care Providers - UPDATE on Type III Endoleaks

Based on new information, the Endologix AFX with Strata device is at greater risk for a Type III endoleak compared to other endovascular AAA graft systems.

FDA - U.S. Food and Drug Administration

4-6-2018

Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL in the Carpuject™ Single-use Cartridge Syringe System   by Hospira: Recall - Due to the Potential Presence of Particulate Matter

Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL in the Carpuject™ Single-use Cartridge Syringe System by Hospira: Recall - Due to the Potential Presence of Particulate Matter

The patient has a low likelihood of experiencing adverse events ranging from local irritation, allergic reactions, phlebitis, end-organ granuloma, tissue ischemia, pulmonary emboli, pulmonary dysfunction, pulmonary infarction, and toxicity.

FDA - U.S. Food and Drug Administration

30-5-2018

Risks and benefits of plant protection products containing neonicotinoids compared with their alternatives

Risks and benefits of plant protection products containing neonicotinoids compared with their alternatives

In 2016, as part of the implementation of the Act "for the restoration of biodiversity, nature and landscapes” and as requested by the Ministries of Agriculture, Health and Ecology, ANSES initiated an assessment weighing up the risks and benefits of plant protection products containing neonicotinoids, compared with their chemical and non-chemical alternatives. Today, ANSES is publishing its final opinion. For most uses of plant protection products containing neonicotinoids, sufficiently effective and ope...

France - Agence Nationale du Médicament Vétérinaire

26-4-2018

Nota Informativa Importante su azitromicina (02/05/2018)

Nota Informativa Importante su azitromicina (02/05/2018)

L'Agenzia Italiana del Farmaco rende disponibili nuove e importanti informazioni riguardo l'aumento del tasso di recidive delle neoplasie ematopoietiche e della mortalità nei pazienti sottoposti a trapianto di cellule staminali ematopoietiche (HSCT) che assumono azitromicina.

Italia - AIFA - Agenzia Italiana del Farmaco

5-7-2011

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines in ATC group C01 (cardiac therapy)

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines in ATC group C01 (cardiac therapy)

At the request of the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group C01 – cardiac therapy. These medicines are used for the treatment of cardiac arrhythmia (e.g. atrial fibrillation) and heart cramps (angina pectoris).

Danish Medicines Agency

17-9-2018

Scientific guideline:  Concept paper on the need for revision of the guideline on the investigation of medicinal products in the term and preterm neonate - Revision 1, draft: consultation open

Scientific guideline: Concept paper on the need for revision of the guideline on the investigation of medicinal products in the term and preterm neonate - Revision 1, draft: consultation open

The Guideline on the investigation of medicinal products in the term and preterm neonates was prepared during the period from 2007 to 2009 and came into effect in 2010 (EMEA/536810/2008). Considerable experience of assessing PIP applications covering neonatal age subset has been gained since then and it has become apparent that some essential questions arise repeatedly during the assessment of Paediatric Investigation Plans (PIP) applications for products intended to be investigated and used in neonates....

Europe - EMA - European Medicines Agency

11-9-2018

 Risk assessment guideline focus group meeting, European Medicines Agency, London, UK, From: 19-Sep-2018, To: 19-Sep-2018

Risk assessment guideline focus group meeting, European Medicines Agency, London, UK, From: 19-Sep-2018, To: 19-Sep-2018

The Antimicrobials Working Party of the European Medicines Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) is holding a focus group meeting with stakeholders to discuss the revision of the antimicrobial veterinary medicinal product risk assessment guideline, following a public consultation on the draft revised guideline ending on 31 October 2018. The meeting will focus on topics identified during this public consultation. This guideline aims to provide guidance to marketing authorisat...

Europe - EMA - European Medicines Agency

17-8-2018

Scientific guideline:  Draft guideline on clinical investigation of medicinal products in the treatment of epileptic disorders - Revision 3, draft: consultation open

Scientific guideline: Draft guideline on clinical investigation of medicinal products in the treatment of epileptic disorders - Revision 3, draft: consultation open

The present document is a third revision of the existing guideline. It should be considered as general guidance on the development of medicinal products for the treatment of epileptic disorders and should be read in conjunction with other EMA and ICH guidelines, which may apply to these conditions and patient populations. The main changes to the existing guideline include incorporation of the new classification / definitions of seizure types and epilepsies, the acceptance of add-on studies in support o...

Europe - EMA - European Medicines Agency

27-7-2018

Scientific guideline:  Reflection paper on dose optimisation of established veterinary antibiotics in the context of summary of product characteristics (SPC) harmonisation, draft: consultation open

Scientific guideline: Reflection paper on dose optimisation of established veterinary antibiotics in the context of summary of product characteristics (SPC) harmonisation, draft: consultation open

Established veterinary antibiotics are not always used at the authorised dose, and the dose may need to be reviewed in order to maintain their effectiveness whilst limiting the risks of antimicrobial resistance. Before a new dose is introduced, the company would typically have to conduct new studies to ensure it does not negatively affect the safety of the target animal, the consumer of animal produce, or the environment. This may reduce product availability, which could have a negative impact on antimic...

Europe - EMA - European Medicines Agency

9-7-2018

Scientific guideline:  Concept paper on the need to develop a reflection paper on development of medicinal products to prevent and treat acute kidney injury, draft: consultation open

Scientific guideline: Concept paper on the need to develop a reflection paper on development of medicinal products to prevent and treat acute kidney injury, draft: consultation open

The concept paper will include discussion of and recommendations for the requirements for evaluation and development of medicinal products for the prevention and/or treatment of acute kidney injury (AKI) and its long-term complications. Relevant topics for discussion include patient populations, endpoints, study methodology, and study duration.

Europe - EMA - European Medicines Agency

10-5-2018

Comunicazione EMA su medicinali contenenti metamizolo (01/06/2018)

Comunicazione EMA su medicinali contenenti metamizolo (01/06/2018)

L'Agenzia Europea per i Medicinali (EMA) comunica che ha avviato una revisione dei medicinali contenenti l'antidolorifico metamizolo, che viene utilizzato in diversi Stati membri dell'UE per il trattamento del dolore severo e della febbre che non possono essere controllati con altri trattamenti.

Italia - AIFA - Agenzia Italiana del Farmaco